You searched for Gout - Page 5 of 90

Abstract Number: 2023 • ACR Convergence 2024
A PEGylated Mammalian Uricase Suitable for Intramuscular Administration to Patients with Refractory Chronic Gout
Frank Fan¹, Riyong Liu¹ and Yu Wang², ¹Chongqing PegBio Biopharm Co.,Ltd., Chongqing, China (People's Republic), ²Hangzhou Grand Biologic Pharmaceutical, Inc., Hangzhou, China (People's Republic)
Background/Purpose: For patients with refractory chronic gout, i.e., those who have frequent gout flares and/or persistent tophi despite treatment with the highest tolerable doses of…
Abstract Number: 2024 • ACR Convergence 2024
Serum Urate Change Among Patients with Gout Treated with Anti-Hypertensive Medications: A Comparative Effectiveness Analysis
Chio Yokose¹, saiajay chigurupati², Bohang Jiang², Kiara Tan², Natalie McCormick² and Hyon K. Choi³, ¹Massachusetts General Hospital, Waltham, MA, ²Massachusetts General Hospital, Boston, MA, ³Massachusetts General Hospital, Lexington, MA
Background/Purpose: Hypertension is the most common comorbidity among patients with gout, with a prevalence of nearly 75% among patients with gout. Losartan and calcium channel…
Abstract Number: 2123 • ACR Convergence 2024
Epidemiology of Bone Health and Fracture in Gout Patients
Emily Holladay¹, Alexis Woods², Lissa Padnick-Silver³, Fenglong xie⁴, Jingyi Zhang⁵, Angelo Gaffo⁵, Jeffrey Curtis⁶ and Brian LaMoreaux², ¹University of Alabama at Birmingham, Edmond, OK, ²Amgen, Thousand Oaks, CA, ³Amgen, Thousand Oaks, ⁴University of Alabama at Birmingham; Illumination Health, Birmingham, AL, ⁵University of Alabama at Birmingham, Birmingham, AL, ⁶FASTER Medicine, Hoover, AL
Background/Purpose: Gout is an erosive arthropathy, and gout patients have been shown to have a higher occurrence of osteoporosis and fracture. This study evaluated bone…
Abstract Number: 2557 • ACR Convergence 2024
The Relation of Colchicine to Knee/hip Replacement Among People with Gout in a Population-based Cohort Study
Zhiqiang Wang¹, Sarah Tilley², Christine Peloquin², Eva Petrow³, Margaret Clancy² and Tuhina Neogi², ¹Clinical Research Centre, Zhujiang Hospital, Southern Medical University, Guangzhou, China, Guangzhou, Guangdong, China (People's Republic), ²Boston University Chobanian & Avedisian School of Medicine, Boston, MA, ³Boston Medical Center, Boston, MA
Background/Purpose: Colchicine, an anti-inflammatory drug commonly used in gout, has been associated with a lower incidence of total knee/hip replacement compared to placebo among participants…
Abstract Number: 2559 • ACR Convergence 2024
Relationship Between Serum Urate and Changes in Dual Energy Computed Tomography MSU Crystal Volume over One Year in People with Gout: An Individual Participant Data Analysis
Brooke Kelly¹, Gregory Gamble¹, Anne Horne¹, Anthony Doyle¹, Jill Drake², Opetaia Aati¹, Chang-Nam Son¹, Ramanamma Kalluru³, Kieran Latto¹, Lisa Stamp⁴ and Nicola Dalbeth¹, ¹University of Auckland, Auckland, New Zealand, ²University of Otago, Christchurch, New Zealand, ³Health New Zealand, Auckland, New Zealand, ⁴University of Otago, Christchurch, Christchurch, New Zealand
Background/Purpose: The dynamics of monosodium urate (MSU) crystal changes across a range of serum urate concentrations in people with gout are unknown. The aim of…
Abstract Number: 2560 • ACR Convergence 2024
Continuous Reduction in Ultrasound Detected Crystal Depositions over 5 Years Follow-up: Results from the NOR-Gout Study
Hilde B Hammer¹, Lars F Karoliussen¹, Lene Terslev², Espen A. Haavardsholm³ and Tillmann Uhlig¹, ¹Diakonhjemmet hospital, Oslo, Norway, ²Rigshospitalet-Glostrup & COPECARE, Glostrup, Denmark, ³Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, and University of Oslo (UiO), Institute of Clinical Medicine, Oslo, Norway, Oslo, Norway
Background/Purpose: Ultrasound (US) is sensitive for detecting monosodium urate (MSU) crystal depositions in gout, described as double contour (DC), tophi and aggregates. Depositions decreased during…
Abstract Number: 2561 • ACR Convergence 2024
Circulating Proteomic Profiles and Incident Gout Risk: Prospective Cohort Study of >48,000 Men and Women
Natalie McCormick¹, Amit Joshi², Robert Terkeltaub³, Tony Merriman⁴, Matthew Nayor⁵, Chio Yokose⁶ and Hyon K. Choi⁷, ¹Massachusetts General Hospital, Boston, MA, ²Channing Division of Network Medicine, Boston, MA, ³Retired, San Diego, CA, ⁴University of Alabama at Birmingham, Homewood, AL, ⁵Boston University Chobanian & Avedisian School of Medicine, Boston, MA, ⁶Massachusetts General Hospital, Waltham, MA, ⁷Massachusetts General Hospital, Lexington, MA
Background/Purpose: Detailed characterization of the plasma proteome may provide insights into the dynamic molecular changes preceding gout. A previous cross-sectional study of pre-existing gout (n=330…
Abstract Number: L15 • ACR Convergence 2023
AR882, an Efficacious and Selective URAT1 Inhibitor for Patients with Chronic Gouty Arthritis and Subcutaneous Tophi: Results from a Global, Prospective, Proof-of-Concept Trial Using Dual Energy Computed Tomography
Robert Keenan¹, James Cheng-Chung WEI², Sarah Morris³, Pamella Mundell³, Wen Wei³, Ke Shi³, Zancong Shen³, Vijay Hingorani⁴, Shunqi Yan³, Bahram Kiani⁵ and Litain Yeh³, ¹Arthrosi Therapeutics, Inc., Chapel Hill, NC, ²Chung Shan Medical University, Taichung, Taiwan (Republic of China), ³Arthrosi Therapeutics, Inc., San Diego, CA, ⁴Vanguard Healthsciences, Inc., San Diego, CA, ⁵Wake Forest University School of Medicine, Winston-Salem, NC
Background/Purpose: AR882 is a novel and selective URAT1 inhibitor currently in clinical stage development for the treatment of gout and tophaceous gout and has demonstrated…
Abstract Number: 0048 • ACR Convergence 2023
Monosodium Urate Crystals Activate an Immune Tolerance Program That Restrains the Activation of Inflammatory Signaling in Macrophages During Gout Flares
Mohnish Alishala¹, Stephen Calderon¹, Anyan Chen¹, Monica Guma², Christopher glass¹ and Isidoro Cobo¹, ¹University of California San Diego, San Diego, CA, ²University of California San Diego, La Jolla, CA
Background/Purpose: Gout is the most frequent form of inflammatory arthritis, with episodes of self-resolving acute inflammation in the joint caused by the deposition of monosodium…
Abstract Number: 0229 • ACR Convergence 2023
Vegetable Consumption and Regular Exercise Are Associated with Better Quality of Life in Gout
HYUNSUE DO and Kiwon Moon, Kangwon National University Hospital, Seoul, South Korea
Background/Purpose: Gout, which is a prevalent form of inflammatory arthritis, is generally considered to be more effectively managed through medication. Besides of maintaining medication, they…
Abstract Number: 0232 • ACR Convergence 2023
Incident Gout After Recombinant Zoster Vaccination in Adults Aged ≥65 Years in the USA
Susan dosReis¹, Chengchen Zhang¹, Alejandro Amill-Rosario¹, Abree Johnson¹, Haeyoung Lee¹, O’Mareen Spence², Driss Oraichi², Harry Seifert², Valentine Franck³, Susan Gamble² and Huifeng Yun², ¹University of Maryland School of Pharmacy, Baltimore, MD, ²GlaxoSmithKline, Rockville, MD, ³GlaxoSmithKline, Wavre, Belgium
Background/Purpose: In pre‑licensure clinical trials, numerical differences in gout cases between the recombinant zoster vaccine (RZV) and placebo groups have been observed. However, real-world evidence…
Abstract Number: 0233 • ACR Convergence 2023
Impaired Anti-oxidant Function of HDL and Its Associated Protein, Paraoxonase-1, in Patients with Gout
John FitzGerald¹, Christina Charles-Schoeman², Veena Ranganath³, Ani Shahbazian⁴, Jennifer Wang¹ and Maureen McMahon⁵, ¹University of California Los Angeles, Los Angeles, CA, ²UCLA Medical Center, Santa Monica, CA, ³David Geffen School of Medicine, UCLA, Los Angeles, CA, ⁴UCLA Rheumatology, Los Angeles, CA, ⁵UCLA David Geffen School of Medicine, Los Angeles, CA
Background/Purpose: Longitudinal cohorts have described the association between gout and cardiovascular disease (CVD), while other cohort and interventional studies (CANTOS) have shown the impact of…
Abstract Number: 0234 • ACR Convergence 2023
Identifying Optimal Serum Urate Levels to Reduce Gout Flares in Patients Taking Urate Lowering Therapy: A Post-hoc Cohort Analysis of CARES with Consideration of Drop-out
Sara Tedeschi¹, Keigo Hayashi¹, Yuqing Zhang², Hyon K. Choi³ and Daniel Solomon¹, ¹Brigham and Women's Hospital, Boston, MA, ²Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, MA, ³Massachusetts General Hospital and Harvard Medical School, Lexington, MA
Background/Purpose: ACR gout treatment guidelines recommend a target serum urate (SU) of < 6 mg/dL and anti-inflammatory flare prophylaxis for at least 3-6 months after…
Abstract Number: 0238 • ACR Convergence 2023
Adherence to the Gout and Crystal Arthritis Network (G-CAN) Consensus Statements for Gout Nomenclature
Ellen Prendergast¹, Nicola Dalbeth², David Bursill³, Chris Frampton⁴ and Lisa Stamp⁴, ¹Te Whatu Ora Southern, Dunedin, New Zealand, ²University of Auckland, Auckland, New Zealand, ³Royal Adelaide Hospital, Kensington Gardens, Australia, ⁴University of Otago, Christchurch, New Zealand
Background/Purpose: Uniform terminology with standardised definitions for the various elements and states of a disease ensure accurate and consistent technical communication. In 2019 the Gout…
Abstract Number: 0239 • ACR Convergence 2023
Incidence and Prevalence of Cardiovascular and Metabolic Diseases Following Gout Diagnosis in the United Kingdom Using the THIN Database
Michael Garshick¹, Haridarshan Patel², ada Kumar², Brian LaMoreaux², Lissa Padnick-Silver², Louis Dron³, Vinusha Kalatharan³, Vivek Verma³ and Michael Pillinger⁴, ¹NYU School of Medicine/NYU Langone Medical Center, New York, NY, ²Horizon Therapeutics, Deerfield, IL, ³Cytel Canada Inc., Vancouver, BC, Canada, ⁴New York University Grossman School of Medicine, New York, NY
Background/Purpose: Gout is a common inflammatory arthropathy characterized by pain, joint swelling, and monosodium urate crystal deposits in joints, organs, and soft tissues.1 While gout…

A PEGylated Mammalian Uricase Suitable for Intramuscular Administration to Patients with Refractory Chronic Gout

Serum Urate Change Among Patients with Gout Treated with Anti-Hypertensive Medications: A Comparative Effectiveness Analysis

Epidemiology of Bone Health and Fracture in Gout Patients

The Relation of Colchicine to Knee/hip Replacement Among People with Gout in a Population-based Cohort Study

Relationship Between Serum Urate and Changes in Dual Energy Computed Tomography MSU Crystal Volume over One Year in People with Gout: An Individual Participant Data Analysis

Continuous Reduction in Ultrasound Detected Crystal Depositions over 5 Years Follow-up: Results from the NOR-Gout Study

Circulating Proteomic Profiles and Incident Gout Risk: Prospective Cohort Study of >48,000 Men and Women

AR882, an Efficacious and Selective URAT1 Inhibitor for Patients with Chronic Gouty Arthritis and Subcutaneous Tophi: Results from a Global, Prospective, Proof-of-Concept Trial Using Dual Energy Computed Tomography

Monosodium Urate Crystals Activate an Immune Tolerance Program That Restrains the Activation of Inflammatory Signaling in Macrophages During Gout Flares

Vegetable Consumption and Regular Exercise Are Associated with Better Quality of Life in Gout

Incident Gout After Recombinant Zoster Vaccination in Adults Aged ≥65 Years in the USA

Impaired Anti-oxidant Function of HDL and Its Associated Protein, Paraoxonase-1, in Patients with Gout

Identifying Optimal Serum Urate Levels to Reduce Gout Flares in Patients Taking Urate Lowering Therapy: A Post-hoc Cohort Analysis of CARES with Consideration of Drop-out

Adherence to the Gout and Crystal Arthritis Network (G-CAN) Consensus Statements for Gout Nomenclature

Incidence and Prevalence of Cardiovascular and Metabolic Diseases Following Gout Diagnosis in the United Kingdom Using the THIN Database

Simple Search Results